| Mutacin 1140 | Streptococcus mutans | Lantibiotic | | Hospital-acquired infections | Multi drug resistant strain | in-vitro | Ghobrial et al.
2009 | | Gastrointestinal tract infections | Oral cavity | - in-vitro
- in-vivo (animal model / human model)
| Hillman et al.
2009 | | Gastrointestinal tract infections | Oral cavity | - in-vitro
- in-vivo (animal model / human model)
| Hillman et al.
2007 | | Gastrointestinal tract infections | Oral cavity | - in-vitro
- in-vivo (animal model / human model)
| Zahradnik et al.
2009 |
|
| Hominicin | Staphylococcus hominis MBBL2-9 | Lantibiotic | | Hospital-acquired infections | Multi drug resistant strain | in-vitro | Kim et al.
2010 |
|
| Gallidermin | Staphylococcus gallinarum T | Lantibiotic | |
| Mutacin B-Ny266 | Streptococcus mutans ATCC 202022 | Lantibiotic | | Hospital-acquired infections | Multi drug resistant strain | - in-vitro
- in-vivo (murine model)
| Mota-Meira et al.
2005 |
|
| Mersacidin | Bacillus sp. strain HIL Y-85,54728 | Lantibiotic | |
